Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADACAL: Adalimumab Strategy in Crohn's Disease
NCT01562951Phase 3Terminated
- Sponsor
- GETECCU
- Start
- Oct 2012
- Primary completion
- Mar 2014
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Adalimumab Arm with Placebo Arm (2 arms). Primary endpoint: Rate of therapeutic failure at 48 weeks. Started Oct 2012; status: terminated.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01562951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01562951.